CD24-CXCR3 CAR-T cells

CD24-CXCR3 CAR-T cells are an experimental chimeric antigen receptor (CAR) T-cell therapy designed to target CD24, a glycosylphosphatidylinositol-anchored protein that acts as a "don't eat me" (DEM) signal frequently overexpressed on B-cell malignancies. These CAR-T cells are further engineered to express the chemokine receptor CXCR3 to enhance their trafficking and infiltration into the tumor microenvironment. By targeting CD24, the therapy aims to activate both adaptive immunity through direct T-cell cytotoxicity and innate immunity by blocking DEM signaling to promote macrophage-mediated phagocytosis. Developed by researchers at the University of Virginia and Weill Cornell Medicine, this approach has demonstrated efficacy in preclinical models of aggressive B-cell lymphoma and acute lymphoblastic leukemia, including models resistant to conventional CD19-targeted CAR-T therapies.

Other names

CD24-CXCR3 CAR-TCD-24-CXCR3 CAR-TCD 24-CXCR3 CAR-T